Advanced Search
Your search returned 63 results
  • Oct 7, 2019
    Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues

    DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has filed a pre-market approval (PMA) supplement with the United States Food and Drug Administration (FDA) for...

  • Aug 20, 2019
    Revenue of $7.5 Billion Increased 1.5% Reported; Increased 3.5% Constant Currency

    DUBLIN, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2020, which ended July 26, 2019. The company reported...

  • Dec 17, 2018
    Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence

    DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system,...

  • Nov 20, 2018
    Revenue of $7.5 Billion Increased 6.1% Reported; Increased 7.5% Organic

    DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2019, which ended October 26, 2018. The company reported second...

  • Nov 21, 2017
    Revenue of $7.1 Billion; GAAP Diluted EPS of $1.48; Non-GAAP Diluted EPS of $1.07

    DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2018, which ended October 27, 2017. The company reported second...

  • Jul 17, 2017
    The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder

    DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...

  • Mar 30, 2016
    New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB

    DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive...

  • Nov 18, 2014
    Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported

    MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014. The company reported worldwide...

  • Oct 7, 2014
    FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence

    MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently...

  • Aug 19, 2014
    Revenue of $4.3 Billion Grew 4% on Constant Currency Basis; 5% as Reported

    MINNEAPOLIS - Aug. 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2015, which ended July 25, 2014. The company reported worldwide...

  • Aug 20, 2013
    Revenue of $4.1 Billion Grew 3% at Constant Currency; 2% as Reported

    MINNEAPOLIS - August 20, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2014, which ended July 26, 2013. The company reported worldwide...

  • May 21, 2013
    Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported

    MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2013, which ended April 26, 2013. The Company reported worldwide...

  • Feb 19, 2013
    Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported

    MINNEAPOLIS - February 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2013, which ended January 25, 2013. The Company reported...

  • Nov 20, 2012
    Revenue of $4.1 Billion Grew 5% on a Constant Currency Basis; 2% as Reported

    MINNEAPOLIS - November 20, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2013, which ended October 26, 2012. The Company reported...

  • Aug 21, 2012
    Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported

    MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...

  • May 22, 2012
    Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported

    MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...

  • Feb 21, 2012
    Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported

    MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...

  • Nov 20, 2011
    Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported

    MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...

  • Aug 23, 2011
    Revenue of $4 Billion Driven by International Growth of 7% on a Constant Currency Basis; 19% as Reported

    MINNEAPOLIS, Aug 23, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2012, which ended July 29, 2011. The Company...

  • Aug 15, 2011
    InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA

    MINNEAPOLIS, Aug 15, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, prospective trial show that sacral nerve stimulation using...

  • May 24, 2011
    Record Fourth Quarter Revenue of $4.3 Billion Driven by Strong International Growth of 12%

    MINNEAPOLIS, May 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 29, 2011. Medtronic recorded fiscal...

  • Apr 1, 2011
    Unique Sacral Nerve Stimulation Therapy Now Available for Treatment of Chronic Fecal Incontinence

    MINNEAPOLIS, Apr 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim(R) Therapy for Bowel Control. InterStim...

  • Feb 20, 2011
    Revenue of $4.0 Billion Grew 3% on Strength of New Products

    MINNEAPOLIS, Feb 22, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2011, which ended January 28, 2011. The company...

  • Nov 29, 2010
    International Revenue of $1.6 Billion Grew 6% on a Constant Currency Basis; 4% As Reported

    MINNEAPOLIS, Nov 23, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2011, which ended October 29, 2010. The company...

  • Nov 1, 2010

    MINNEAPOLIS, Nov 18, 2010 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT), the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA)...

Show 5102550100 per page